Cargando…
Decoding molecular programs in melanoma brain metastases
Melanoma brain metastases (MBM) variably respond to therapeutic interventions; thus determining patient’s prognosis. However, the mechanisms that govern therapy response are poorly understood. Here, we use a multi-OMICS approach and targeted sequencing (TargetSeq) to unravel the programs that potent...
Autores principales: | Radke, Josefine, Schumann, Elisa, Onken, Julia, Koll, Randi, Acker, Güliz, Bodnar, Bohdan, Senger, Carolin, Tierling, Sascha, Möbs, Markus, Vajkoczy, Peter, Vidal, Anna, Högler, Sandra, Kodajova, Petra, Westphal, Dana, Meier, Friedegund, Heppner, Frank, Kreuzer-Redmer, Susanne, Grebien, Florian, Jürchott, Karsten, Redmer, Torben |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701224/ https://www.ncbi.nlm.nih.gov/pubmed/36435874 http://dx.doi.org/10.1038/s41467-022-34899-x |
Ejemplares similares
-
Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients
por: Radke, Josefine, et al.
Publicado: (2019) -
Phospho-AXL is widely expressed in glioblastoma and associated with significant shorter overall survival
por: Onken, Julia, et al.
Publicado: (2017) -
CD271 determines migratory properties of melanoma cells
por: Radke, Josefine, et al.
Publicado: (2017) -
Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo
por: Onken, Julia, et al.
Publicado: (2016) -
Decoding the Role of CD271 in Melanoma
por: Vidal, Anna, et al.
Publicado: (2020)